Clinical trial
Administration of Recombinant Human Growth Hormone in the Knee Joint of Patients Suffering from Osteoarthritis
NCT06354023 is registered in ClinicalTrials.gov with John Sledge as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Administration of Recombinant Human Growth Hormone in the Knee Joint of Patients Suffering from Osteoarthritis
- Lead sponsor
- John Sledge
- Phase
- Phase 2
- Overall status
- Suspended
- Start date
- February 8, 2025
- Completion date
- February 8, 2026
- Enrollment
- 23 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.